Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Intrinsic Value Partners LLC

Intrinsic Value Partners LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 91.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,392 shares of the company's stock after purchasing an additional 24,505 shares during the quarter. Moderna makes up 3.4% of Intrinsic Value Partners LLC's portfolio, making the stock its 9th biggest holding. Intrinsic Value Partners LLC's holdings in Moderna were worth $3,435,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter worth $26,000. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after acquiring an additional 90 shares during the period. Family Firm Inc. acquired a new position in Moderna during the 2nd quarter valued at about $33,000. Bank & Trust Co acquired a new position in Moderna during the 2nd quarter worth $36,000. Finally, Hanseatic Management Services Inc. bought a new position in shares of Moderna in the second quarter worth $48,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRNA. JPMorgan Chase & Co. dropped their target price on Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a report on Monday, November 4th. Jefferies Financial Group lowered their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a "sell" rating to a "hold" rating and reduced their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. HSBC raised shares of Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price on the stock in a research report on Wednesday, August 28th. Finally, The Goldman Sachs Group decreased their price objective on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a report on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $93.18.

Moderna Trading Down 8.7 %

NASDAQ:MRNA traded down $4.08 during trading hours on Monday, hitting $42.75. 15,892,516 shares of the stock were exchanged, compared to its average volume of 4,541,268. The company has a quick ratio of 3.92, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $42.25 and a twelve month high of $170.47. The company has a market capitalization of $16.43 billion, a P/E ratio of -7.28 and a beta of 1.69. The company's 50 day moving average is $61.85 and its two-hundred day moving average is $99.09.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.